NDC product
PREVYMIS
NDC 0006-5086 · Merck Sharp & Dohme LLC
Key facts
| Product NDC | 0006-5086 |
|---|---|
| Proprietary name | PREVYMIS |
| Nonproprietary name | LETERMOVIR |
| Substances | LETERMOVIR |
| Dosage form | PELLET |
| Route | ORAL |
| Labeler | Merck Sharp & Dohme LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA219104 |
| Pharmacologic classes | Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A Inhibitors [MoA], Cytomegalovirus DNA Terminase Complex Inhibitor [EPC], DNA Terminase Complex Inhibitors [MoA] and 2 more |
| Marketing start | Aug 30, 2024 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: